Apraglutide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
A once a week version of GLP-2 for short bowel syndrome, where the approved drug, teduglutide, needs a daily shot. In small studies it helped the gut absorb more fluid.
Evidence grade for Apraglutide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 0 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Apraglutide is a once a week shot that copies GLP-2, the gut's own repair signal. It is for short bowel syndrome. That is when so much bowel is gone that people need drip feeding. The approved drug, teduglutide, needs a daily shot. This one is not approved yet.
What people take it for
- Needing less drip feeding with short bowel syndrome.
- A weekly shot instead of a daily one.
What studies in people showed
The studies are small, as they tend to be in rare diseases. In 9 adults who still had their colon, a weekly shot for a year cut drip feeding by about half. 7 of the 9 got at least one day a week off the drip. Everyone knew what they were on, and there was no one to compare against. In 8 adults who tried two doses and a dummy in turn, urine output rose by about 700 to 800 millilitres a day. That means the gut was taking in more fluid. Side effects were mild to moderate.
What people report
Reports, not study results
The good
- Side effects in the small fluid study were mild to moderate.
The bad
- Nobody has compared it head to head with teduglutide.
- The studies had only 8 and 9 people.
Where these come from: From the studies on this page. We have not collected user reports on this one yet.
My bottom line
My opinion: real results for a real disease. It is a gut failure drug, not a gut health or weight loss peptide. If you do not have short bowel syndrome, it is not for you.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Apraglutide?
A once a week version of GLP-2 for short bowel syndrome, where the approved drug, teduglutide, needs a daily shot. In small studies it helped the gut absorb more fluid.
GLP-2 is the gut's own repair signal. It already has an approved drug: teduglutide, for short bowel syndrome with gut failure. Short bowel syndrome means so much bowel has been removed that the rest cannot absorb enough food and water. Many patients are fed through a drip into a vein. Teduglutide adds a daily shot on top of all that.
Apraglutide is built for once a week. The published human work measures everything going into and coming out of the body. That is the right way to test it, because what matters is how much fluid and food the remaining bowel can absorb. In 9 adults who still had their colon connected, a weekly shot for a year cut drip feeding by about half. 7 of the 9 managed at least one day a week off the drip. Everyone knew what they were on, and there was no comparison group. In 8 adults who each tried two doses and a dummy in turn, urine output rose by roughly 700 to 800 millilitres a day on the drug. That is the sign the gut is absorbing more fluid.
It is on this site because GLP-2 is the switch that the other half of dapiglutide aims at. A reader following that drug should be able to see what the GLP-2 path achieves on its own, when it is the point of the drug and not an add-on.
How does Apraglutide work?
It is a long acting copy of glucagon-like peptide-2, a 33 amino acid hormone released by cells in the gut. GLP-2 makes the gut lining grow. The finger-like folds that absorb food get taller, and the pits between them get deeper. It also slows the stomach and gut, and boosts blood flow to the gut. Together these let the gut absorb more. Changes to its structure make it last long enough for a weekly shot, where teduglutide needs a daily one.
What have studies in people found about Apraglutide?
Two published studies in short bowel syndrome with gut failure. Both measured everything going into and out of the body. One looked only at people who still have their colon connected. The numbers are small.
- Colon still connected (2024): 9 adults, a weekly shot for a year, and everyone knew what they got. Drip feeding fell by about half by week 52. 7 of the 9 had at least one day a week off the drip.
- Fluid absorption study (2022): 8 adults who each tried two doses and a dummy. Urine output rose by roughly 700 to 800 millilitres a day on the drug, a sign of better fluid absorption.
- It is a once a week shot, against teduglutide's daily one. For these patients that is a real practical difference, not a marketing one.
What this does not tell you: These are small studies in a rare disease, and small numbers are hard to avoid here. In the year long study, everyone knew what they were on and there was no comparison group. Fluid absorption is the right thing to measure. It is not the same as what patients care about most, which is needing less drip feeding or stopping it. Nothing here compares apraglutide with teduglutide head to head. So the weekly schedule is a known plus, and how well it works next to teduglutide is not known.
The state of the research
This page is here partly for its own sake and partly as a reference point. Dapiglutide, also on this site, pairs GLP-1 with GLP-2, and its weight loss trial missed. A reader might fairly conclude the GLP-2 half does nothing. Apraglutide shows that is the wrong conclusion. Switching on GLP-2 makes real, measurable changes in how much the gut absorbs in people, and there is an approved drug in this family.
The difference is what the path is being asked to do. Repairing and growing the absorbing surface in someone whose bowel was shortened by surgery is a shown effect. Improving the gut lining enough to change body weight in obesity is a different claim, and so far nothing supports it.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2022 and 2024.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Modified GLP-2 analogue peptide. No mass asserted; no source loaded states one.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Long-acting, engineered for once-weekly subcutaneous dosing. No specific figure resolved in the sources loaded.
No amino acid sequence is on file for Apraglutide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2022Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure
It worked, in a small trial, on the thing that matters to these patients. Eight adults with short bowel syndrome who depend on feeding through a drip took weekly apraglutide at two doses and a dummy, each person trying both, in turn, without knowing which. Urine output rose by roughly 700 to 800 millilitres a day on the drug, the sign that the gut is absorbing more fluid. Side effects were mild to moderate. A larger trial followed.
A phase 2 metabolic balance study in patients with short bowel syndrome and intestinal failure, reporting improved fluid absorption. Metabolic balance is the appropriate design here because absorptive capacity, not a symptom score, is the outcome that determines whether a patient can reduce parenteral support.
- Study in people2024Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: a multicenter, open-label, metabolic balance study
Apraglutide roughly halved how much drip feeding these patients needed. Nine adults with short bowel syndrome who still had their colon connected took a weekly injection for a year, with everybody knowing what they were on. By week 52 the volume fed through a drip was down by about half, and seven of the nine managed at least one day a week without it. Nine patients and no comparison group, so nothing says what would have happened anyway.
A multicentre open-label metabolic balance study in the colon-in-continuity anatomy specifically. Anatomy matters in this disease: how much colon remains changes both the absorptive baseline and the expected response, so studying that subgroup separately is a meaningful design choice rather than a subgroup analysis after the fact.
Where to buy Apraglutide
No seller we track lists Apraglutide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Apraglutide been tested in people?
Yes. 0 people given it across 2 completed trials cited here, 0 of which found nothing. A once a week version of GLP-2 for short bowel syndrome, where the approved drug, teduglutide, needs a daily shot. In small studies it helped the gut absorb more fluid.
What is the Apraglutide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 0 people given it
Is Apraglutide FDA-approved?
Investigational for short bowel syndrome. Not approved at the time of this review.
How is apraglutide different from teduglutide?
Both are GLP-2 copies for short bowel syndrome. Teduglutide is approved and needs a daily shot. Apraglutide is built for once a week. These patients already manage drip feeding and daily infusions, so that schedule difference matters. No study has compared how well they work head to head.
Does GLP-2 help with weight loss?
Nothing supports that. What GLP-2 has been shown to do is help the gut absorb and grow its lining. That is why it treats gut failure. The one weight loss trial of a drug containing GLP-2, dapiglutide, missed its main goal. Its gut lining idea has not been tested against a real health result in people.
What is a metabolic balance study?
A study where everything going into and coming out of the body is measured, so absorption can be worked out directly instead of guessed. For short bowel syndrome it is the right approach, because the question is literally how much the remaining bowel can absorb.